Evidence map›Paper›PMID 40788991›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Lenvatinib Plus Paclitaxel as Second-Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study.

Chenfei Zhou, Jinling Jiang, Liting Guo, Wenqi Xi, Junwei Wu, Qu Cai, Jun Ji, Feng Qi, Jun Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chenfei ZhouDepartment of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Jinling JiangDepartment of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Liting GuoDepartment of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Wenqi XiDepartment of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Junwei WuDepartment of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Qu CaiDepartment of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Jun JiShanghai Institute of Digestive Surgery, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Feng QiDepartment of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.ORCID https://orcid.org/0000-0003-2527-8212
Jun ZhangDepartment of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Funding

National Natural Science Foundation of China 82202874National Natural Science Foundation of China 82273126Shanghai Municipal Health Bureau Project 2020CXJQ03State Scholarship Fund of China Scholarship Council 202206235017
6 · The paper itself

Abstract

Second-line treatment options for advanced gastric cancer (AGC) patients remain limited. This dose escalation exploratory study is aimed to determine the maximum tolerated dose (MTD) of lenvatinib plus paclitaxel as second-line treatment in AGC and to explore molecular biomarkers using dynamic network biomarker (DNB) analysis. Eligible patients are treated with lenvatinib plus paclitaxel (135 mg m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsPaclitaxelPhenylurea CompoundsQuinolinesStomach NeoplasmsAdultAgedFemaleHumansMaleMaximum Tolerated DoseMiddle AgedTreatment OutcomelenvatinibPaclitaxelPhenylurea CompoundsQuinolinesdose escalationdynamic network biomarkergastric cancerlenvatinib, second‐line

Identifiers

PMID40788991
PMCPMC12561184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.